NasdaqGM:CRVSBiotechs
Could Corvus Pharmaceuticals’ (CRVS) New Board Appointment Reframe Its Immunology Strategy And Competitive Edge?
In April 2026, Corvus Pharmaceuticals, Inc. appointed Andrew C. Chan, M.D., Ph.D., former Senior Vice President, Research Biology at Genentech and a leading immunology expert, to its Board of Directors.
By adding a director with decades of experience translating T cell biology into approved therapies, Corvus is deepening the scientific guidance around its ITK inhibitor soquelitinib and broader immunology pipeline.
Next, we’ll explore how Dr. Chan’s deep immunology and drug development...